• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.

作者信息

Lu Kevin

机构信息

School of Medicine, I-Shou University, Kaohsiung City, Taiwan; Division of Urology, Department of Surgery, E-Da Hospital, Kaohsiung City, Taiwan; Division of Urology, E-Da Cancer Hospital, Kaohsiung City, Taiwan.

出版信息

Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.

DOI:10.1016/j.eururo.2015.08.017
PMID:26318711
Abstract
摘要

相似文献

1
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.回复：奥拉齐奥·卡福、乌戈·德·乔治、露西亚·弗拉蒂诺等。多西他赛及其他二线治疗失败后作为三线或四线治疗的去势抵抗性前列腺癌治疗的临床结果：一项意大利多中心研究的结果。《欧洲泌尿外科杂志》2015年；68卷：147 - 153页
Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.
2
Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.
3
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.多西他赛和其他二线治疗失败后作为三线或四线治疗的去势抵抗性前列腺癌治疗的临床结局：意大利多中心研究的结果。
Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.
4
The third line of treatment for metastatic prostate cancer patients: Option or strategy?转移性前列腺癌患者的三线治疗：选择还是策略？
Crit Rev Oncol Hematol. 2015 Sep;95(3):265-71. doi: 10.1016/j.critrevonc.2015.04.010. Epub 2015 May 21.
5
Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.回复：罗伯特·J·范·索斯特、埃伦·S·德·莫雷、夏洛特·F·克韦尔丹等。在去势抵抗性前列腺癌中，靶向雄激素受体可导致恩杂鲁胺和多西他赛之间产生体内交叉耐药，但卡巴他赛不会。《欧洲泌尿外科杂志》2015年；67卷：981 - 985页。
Eur Urol. 2016 Mar;69(3):e41-2. doi: 10.1016/j.eururo.2015.07.025. Epub 2015 Jul 26.
6
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.回复盐田正树和横沟晃的致编辑信：关于罗伯特·J·范·索斯特、埃伦·S·德·莫雷、夏洛特·F·克韦尔丹等人的研究“靶向雄激素受体在去势抵抗性前列腺癌中赋予恩杂鲁胺和多西他赛之间的体内交叉耐药性，但卡巴他赛不存在这种情况”。《欧洲泌尿外科杂志》2015年；67卷：981 - 985页
Eur Urol. 2016 Mar;69(3):e43-4. doi: 10.1016/j.eururo.2015.07.024. Epub 2015 Jul 30.
7
Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?前列腺癌的腮腺转移：多西他赛仍是最佳治疗选择吗？
Anticancer Drugs. 2015 Mar;26(3):367-70. doi: 10.1097/CAD.0000000000000188.
8
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.醋酸阿比特龙用于多西他赛治疗失败后的转移性去势抵抗性前列腺癌：一项随机、双盲、安慰剂对照的3期桥接研究。
Int J Urol. 2016 May;23(5):404-11. doi: 10.1111/iju.13051. Epub 2016 Feb 15.
9
Towards random sequencing or precision medicine in castration-resistant prostate cancer?去势抵抗性前列腺癌是走向随机测序还是精准医学？
Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. Epub 2013 Sep 19.
10
Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.多西他赛和阿比特龙治疗转移性去势抵抗性前列腺癌失败后使用恩杂鲁胺。
Eur J Cancer. 2014 Mar;50(5):1040-1. doi: 10.1016/j.ejca.2013.12.017. Epub 2014 Jan 22.